2017
DOI: 10.1016/j.cjca.2017.06.001
|View full text |Cite
|
Sign up to set email alerts
|

Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial

Abstract: COMPASS will provide information on the efficacy and safety of rivaroxaban, alone or in combination with aspirin, in the long-term management of patients with stable CAD or PAD, and on the efficacy and safety of pantoprazole in preventing upper GI complications in patients receiving antithrombotic therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
61
0
21

Year Published

2018
2018
2022
2022

Publication Types

Select...
8

Relationship

4
4

Authors

Journals

citations
Cited by 152 publications
(82 citation statements)
references
References 37 publications
0
61
0
21
Order By: Relevance
“…Alternatively, some data indicate that PPIs decrease dabigatran bioavailability, 25,26 with the potential for reduced anticoagulation and decreased bleeding risk. The in-progress COMPASS trial 27 will provide further data on the benefits and risks of PPI co-therapy during anticoagulant treatment.…”
Section: Discussionmentioning
confidence: 99%
“…Alternatively, some data indicate that PPIs decrease dabigatran bioavailability, 25,26 with the potential for reduced anticoagulation and decreased bleeding risk. The in-progress COMPASS trial 27 will provide further data on the benefits and risks of PPI co-therapy during anticoagulant treatment.…”
Section: Discussionmentioning
confidence: 99%
“…25 The effect of proton-pump inhibitor therapy on reducing GIT bleeding risk with rivaroxaban and dabigatran is unknown and remains a subject of ongoing randomised control trials. 26,27 Patients 1, 4, and 5 were on established gastroprotective regimens for alternative reasons prior to the GIT bleeding event, and this remained unchanged following IDA management. Patient 3 did not receive gastroprotective therapy at her choice and experienced resolution of IDA despite this.…”
Section: Discussionmentioning
confidence: 99%
“…Populacja ze SCAD obejmowała 24 824 chorych. Zarówno obszerną kwalifikację, jak i szczegółowe kryteria włączenia opisano w odrębnej pracy [33]. U chorych ze SCAD leczonych naczyniową dawką riwaroksabanu 2 razy 2,5 mg z ASA w dawce 100 mg (DAT) w porównaniu z monoterapią ASA w dawce 100 mg stwierdzono istotną redukcję ryzyka pierwotnego (zgon sercowo-naczyniowy, zawał serca, udar mózgu), złożonego punktu końcowego (4,0% vs. 6,0%, HR 0,74 [95% CI 0,65-0,86]), śmiertelności sercowo--naczyniowej (1,6% vs. 2,2%, HR 0,75 [95% CI 0,60-0,90]), śmiertelności całkowitej (3,0% vs. 4,0%, HR 0,77 [95% CI 0,65-0,90]) [3].…”
Section: Leczenie Przeciwzakrzepowe W Miażdżycowej Chorobie Tętnic Wiunclassified